Table 3.
Baseline characteristics of patients with PH due to COPD.
|
Mild-to-moderate PH due to COPD (N = 144) |
Severe PH due to COPD (N = 130) |
|
|---|---|---|
| Age, years | 72.0 [65.0, 76.3] | 69.0 [64.0, 78.0] |
| n with data | 144 | 130 |
| Male sex, n (%) | 86 (60) | 84 (65) |
| n with data | 144 | 130 |
| Body mass index, kg/m2 | 24.9 [21.5, 29.6] | 24.3 [22.3, 27.6] |
| n with data | 144 | 130 |
| FEV1, % pred | 39.0 [28.8, 55.7] | 50.5 [32.2, 68.2] |
| n with data | 137 | 128 |
| FEV1/VC max | 48.2 [40.2, 60.0] | 55.2 [47.0, 65.5] |
| n with data | 125 | 115 |
| FVC, % pred | 66.3 ± 21.6 | 72.2 ± 23.7 |
| n with data | 116 | 114 |
| TLC, % pred | 114 [99.0, 125] | 105 [91.5, 117] |
| n with data | 130 | 123 |
| DLCO, % pred | 40.2 [27.4, 50.7] | 32.3 [24.6, 43.6] |
| n with data | 71 | 80 |
| mPAP, mm Hg | 28.0 [26.0, 31.0] | 40.0 [36.0, 46.0] |
| n with data | 144 | 130 |
| PVR, dyn·s/cm5 | 299 [248, 368] | 542 [427, 699] |
| n with data | 130 | 107 |
| Cardiac index, L/min/m2 | 2.84 [2.45, 3.28] | 2.40 [1.90, 2.86] |
| n with data | 144 | 129 |
| SvO2, % | 68.8 [64.2, 71.9] | 64.5 [58.7, 69.4] |
| n with data | 143 | 128 |
| RAP, mm Hg | 4.00 [2.00, 6.00] | 5.50 [3.00, 9.00] |
| n with data | 143 | 128 |
| BNP, pg/mL | 55.0 [23.0, 128] | 165 [57.0, 355] |
| n with data | 122 | 110 |
| 6MWD, m | 271 ± 102 | 241 ± 105 |
| n with data | 110 | 101 |
| TAPSE/PASP ratio, mm/mm Hg | 0.407 [0.309, 0.555] | 0.286 [0.207, 0.356] |
| n with data | 88 | 91 |
| Targeted PH therapy, n (%) | ||
| No | 82 (57) | 30 (23) |
| Yes | 57 (40) | 93 (72) |
| Combination therapy | 3 (2.1) | 4 (3.1) |
| Monotherapy | 54 (38) | 89 (68) |
| Phosphodiesterase 5 inhibitor | ||
| No | 2 (1.4) | 17 (13) |
| Yes | 55 (38) | 76 (58) |
| Endothelin receptor antagonist | ||
| No | 54 (38) | 75 (58) |
| Yes | 3 (2.1) | 18 (14) |
Data are presented as median [interquartile range], mean ± standard deviation or n (%). Numbers of patients with available data are shown in italics. 6MWD, 6-min walk distance; % pred, % predicted; BNP, brain natriuretic peptide; DLCO, lung diffusing capacity for carbon monoxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; max, maximum; mPAP, mean pulmonary artery pressure; PASP, pulmonary artery systolic pressure; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; RAP, right atrial pressure; SvO2, mixed venous oxygen saturation; TAPSE, tricuspid annular plane systolic excursion; TLC, total lung capacity; VC, vital capacity.